John Hsuan, the president of Meridigen Biotech Co., Ltd was focusing on the revolutionized medical innovation in the next 50 years. Yogi Hsuan, the General Manager of Meridigen informed that Meridigen was making a concentrated effort to the development of stem cell new drug on the 5th Shanghai and Taipei Forum in 2015 held together by the Want Daily and the Counsellor’s Office of the Shanghai Municipal Government. So far, Meridigen already had the largest placenta-derived stem cell storage in the world, and was planning on building a plant for manufacturing products for human treatment, preparing to enter human clinical trial on a global basis.

Mesenchymal stem cell possessing the ability to renew and repair was the hope for future medical treatment. Many orphan diseases without medical treatment were anticipated to be treated via stem cell infusion. The first case of treating cerebral palsy via autologous cord blood stem cell transplantation was in Singapore in 2009. The entire therapy only took 30 minutes and the patient was allowed to discharge from the hospital the next day. As the evolution of stem cell new drug, people might be treated with stem cell even without storing their own cord blood stem cell at birth.

Yogi Hsuan was invited to give a speech on biotech industry development upon the group forum of the 5th Shanghai and Taipei forum in 2015. Yogi Hsuan indicated that John Gurdon, an English developmental biologist and Shinya Yamanaka, the director of the Center for iPS Cell Research and Application in Japan were both awarded the Nobel Prize in physiology or Medicine in 2012, which meant that the stem cell treatment was approved by the world. As the regulations on stem cell treatment were enacted and promulgated, the stem cell treatment had become more standardized. After the first product of mesenchymal stem cell was introduced in 2011, more and more products were launched to the market.

Businesses of Meridigen included new drug research and development, stem cell storage and prenatal testing. Now, Meridigen had the largest cell storage of placenta and umbilical cord derived mesenchymal stem cells. In addition, Meridigen aimed to build a PIC/S GMP plant for the manufacturing of products for clinical treatment, and prepare to enter human clinical trial on a global basis. Meridigen even integrated in the fields of electronic engineering, informatics, biotechnology and biomedical engineering, etc., as well as working on a large-scale analysis in the characteristics of mesenchymal stem cells and cell identification.

Yogi Hsuan indicated that Meridigen was anticipated to bring its exclusive expertise of placenta derived mesenchymal stem cell storage, technology of research and development, prenatal and genetic testing to China. Since medical care was belong to the infrastructures, Meridigen was willing to participate in the Belt and Road with the goal of interconnecting and intercommunicating of infrastructures in Asia.

Published in Want Daily, Apr. 04 2015